Simpson2013 - Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder, A Randomized Clinical Trial
- Type:#article
- Year read:#read2022
- Subject: OCD CBT
- Bibtex: @simpson2013
- Bibliography: Simpson, H. B., Foa, E. B., Liebowitz, M. R., Huppert, J. D., Cahill, S., Maher, M. J., McLean, C. P., Bender, J., Marcus, S. M., Williams, M. T., Weaver, J., Vermes, D., Van Meter, P. E., Rodriguez, C. I., Powers, M., Pinto, A., Imms, P., Hahn, C.-G., & Campeas, R. (2013). Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 70(11), 1190. https://doi.org/10.1001/jamapsychiatry.2013.1932
Example citation
EX/RP is a more effective augmentation to SRIs than risperidone [@simpson2013].
Risperidone did not outperform pill placebo as an augmentation of treatment with SRIs [@simpson2013]
Key takeaways
- All patients had SRI treatment for at least 12 weeks with moderate OCD. n = 100
- Risperidone (8 weeks trt, n = 40) vs EX/RP (17 sessions 2/week, n = 40) vs placebo (n = 20)
- EX/RP outperformed risperidone YBOCS -9.72 (SE = 1.38), risperidone did not perform better than placebo.
- Responders: 80% EX/RP, 23% risperidone, 15% placebo. Remission 43% EX/RP, 13% risperidone, 5% placebo
Adding EX/RP to SRIs was superior to risperidone and pill placebo in reducing OCD symptoms and improving insight, functioning, and quality of life. Risperidone was not superior to placebo on any outcome.
